{"database": "lobbying", "table": "lobbying_activities", "rows": [[1191167, "deacd640-8797-4c16-a00e-a2f612f7bead", "Q4", "SHIRE PHARMACEUTICALS LLC", 323477, "SHIRE PHARMACEUTICALS LLC", 2011, "fourth_quarter", "PHA", "S. 296, Preserving Access to Life Saving Medicines Act; H.R. 3737, Unlocking Lifesaving Treatments for Rare-Diseases Act (ULTRA); Life Sciences Investment Act\nIssues relating to R&D funding for rare disease products, biosimilars and other products; end stage renal disease (ESRD) orphan drugs; reimbursements; drug shortages; DEA quotas; prescription drug user fees; exclusivity periods", "HOUSE OF REPRESENTATIVES,SENATE", null, 110000, 0, 0, "2012-01-18T14:22:18-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1191167"], "units": {}, "query_ms": 0.3119399771094322, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}